“The present condition has exposed some structural weaknesses during the EU’s medicines source chain in addition to a large dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides said. She proposed that offer chain troubles be tackled within an EU pharmaceutical system expected being introduced by the